Inspiring Scientific Discovery
Search hundreds of thousands of products backed by our one-year, replacement or money-back, satisfaction guarantee.
What's New at Bioss?
The emergence of a novel human coronavirus, named SARS-CoV-2, has become a global health concern causing severe respiratory tract infections in humans. Same as the SARS-CoV found in 2003, phylogenetic analysis revealed that SARS-CoV-2 also belongs to beta genus coronavirus.
Haven't worked with Bioss Antibodies before? Try one of our 20uL trial-sized vials for just $0.01 plus shipping. Click here to view program details and to request your discount code for this promotional pricing.
- Why do many researchers prefer polyclonal antibodies for an IHC/IF assay?Both of monoclonal and polyclonal antibodies are extensively used in IHC/IF assays. However, the staining results for a given monoclonal antibodies are quite unpredictable in different samples as compared to the polyclonal antibodies. It is very interesting to reveal the reasons underlying the performance.
- Scientists are creating new coronavirus vaccines—but may come too lateWith infections of a novel coronavirus exploding in China—case numbers soared to more than 2700 the past 24 hours—and racing around the world, scientists contend they are better prepared than ever to produce a vaccine at Hollywood speed.
- Aβ accumulation, the cause or effect of Alzheimer disease?Regarding the etiology of Alzheimer's disease, the beta amyloid (Aβ) hypothesis has been the most important and experimentally tested theory in the past few decades. However, the research therapies based on this hypothesis have been “falling in the dark” in clinical trials, which has led researchers to rethink the role of “beta amyloid”.
Bioss Pathway Maps
Diving into a new project? Get up to speed quickly with these cellular and molecular pathway maps. Each one is expertly researched and hand-drawn by our scientific team. Autophagy, Tumor Immunology, MAPK, WNT Signaling, and many others are available to download, print, and share at your convenience.
Bioss Inc is a leading antibody developer and manufacturer with state of the art technologies. We have developed over 11,000 primary antibodies and more than 130,000 derived products including fluorochrome conjugated antibodies. In addition to reliable loading control and tag antibodies, our catalog includes over 1000 specific antibodies recognizing proteins with phosphorylation, acetylation, or methylation modifications.